Financial Brief
Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes.
The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.
The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.
The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.
A Bill & Melinda Gates Foundation strategic investment to tackle bacterial vaginosis and improve maternal and neonatal health outcomes worldwide.
The first-in-human study double-blind, placebo controlled, 28-day crossover study of the safety and tolerability of SB-121
